INTRODUCTION
The peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive malignancies derived from mature (postthymic) T lymphocytes that comprise between 5% and 10% of all non-Hodgkin lymphomas (NHLs) diagnosed in Western countries.
1,2 Nodal PTCLs are the most common of the PTCL subtypes and include peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS); anaplastic large cell lymphoma (ALCL); and angioimmunoblastic T-cell lymphoma (AITL). 3, 4 Although PTCL-NOS is the most common of the nodal PTCL subtypes, representing approximately 25% of all PTCLs, it is largely a diagnosis of exclusion that is made when typical features of better defined PTCL subtypes are not present. 5 Less common PTCLs include extranodal and leukemic PTCLs such as extranodal natural killer (NK)/T-cell lymphoma, T-cell prolymphocytic leukemia, and hepatosplenic T-cell lymphoma, among others. 6 The majority of clinical practice guidelines recommend initial treatment of nodal PTCLs either on a therapeutic clinical trial or with regimens that initially were developed for patients with B-cell lymphoma, such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). [6] [7] [8] However, the use of CHOP in patients with PTCL has been associated with suboptimal 5-year overall survival rates ranging from 32% to 43% for PTCL-NOS and 32% to 36% for AITL. 4, [9] [10] [11] A notable exception to the poor long-term prognosis associated with CHOP therapy in patients with PTCL is anaplastic lymphoma kinase (ALK)-positive ALCL, which is associated with 5-year overall survival rates of up to 70% after therapy with CHOP. 4, 12 In an effort to improve on the poor results noted among patients with PTCL-NOS and AITL, hematopoietic stem cell transplantation (HSCT) has been proposed for patients achieving complete remission after induction therapy; however, to the best of our knowledge, there are no randomized trials published to date demonstrating a survival benefit for HSCT in this setting. [13] [14] [15] [16] To better understand the clinical characteristics, treatment patterns, and outcomes in patients with PTCL, the Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE) study was initiated in 2010 (ClinicalTrials.gov identifier NCT01110733). In the current study, we present the first publication of the treatments administered to COMPLETE study enrollees, focusing on those individuals with aggressive nodal PTCL subtypes.
MATERIALS AND METHODS

Study Design
COMPLETE is a prospective multicenter cohort study of patients with newly diagnosed PTCL in the United States. The primary objective of the study was to describe, in detail, patterns of care for patients with PTCL. Secondary objectives were to document outcomes, identify factors influencing treatment decisions, determine the incidence and severity of selected treatment toxicities, and identify supportive care received (protocol available online).
Ethics
The protocol was approved by the Institutional Review Board of each participating institution. All study participants or participants' guardians provided written informed consent before study entry.
Study Eligibility
Patients with a new diagnosis of histologically confirmed PTCL were eligible for enrollment in the COMPLETE study until 30 days after the initiation of the first lymphoma-directed therapy. The following T-cell and NK-cell malignancies were excluded from COMPLETE: precursor T-cell/NK-cell neoplasms, T-cell large granular lymphocytic leukemia, mycosis fungoides (other than transformed mycosis fungoides), Sezary syndrome, and primary cutaneous CD30-positive disorders. Patients participating in clinical trials were not excluded from participation in COMPLETE. No specific target for enrollment was prespecified given the lack of prior studies to inform such projections.
Data Collection and Review for Accuracy
Deidentified data were regularly uploaded onto the study server from each enrolling site as new data became available. Data entered on the Web-based server were subjected to automated error checking that looked for logical inconsistencies, out-of-range values, and missing data. Verification of data accuracy was performed by either the treating physician or site principal investigator, after which the data were locked. Central review of the locked data was performed by a steering committee of experts in PTCL, and queries were generated to verify any data inconsistencies. A separate analysis was performed to verify the accuracy of the histologic data entered at each site through comparison of the uploaded histologic data with the diagnostic pathology reports. 17 
Cohort Selection
Due to the variable natural history and treatments used for the various PTCL subtypes, the study population presented herein was confined to patients with nodal PTCL with a poor prognosis: AITL, PTCL-NOS, and ALCL (ALK negative and ALK positive with an International Prognostic Index [IPI] score of 2-5). For patients with ALCL, we excluded those patients with ALK-positive disease and a low IPI score from the current analyses given their superior prognosis compared with the other patients with nodal PTCLs in the cohort. 18 The remaining patients were stratified into initial treatment groups based on the type of therapy received. The primary outcomes of interest were response rates and overall survival. 
Statistical Analysis
Descriptive statistics were used to summarize the baseline characteristics of the study cohort. For categorical and ordinal variables, frequencies and percentages were calculated. For continuous variables, descriptive statistics (number of patients, mean, median, standard deviation, and range) were provided. Null hypothesis testing used the chi-square, Student t test, and other nonparametric tests as required, with a 2-tailed P value of .05 to reject the null hypothesis. Survival-based analyses were performed using Kaplan-Meier methodology with censoring as appropriate and evaluated using a log-rank test with a 2-tailed P value of .05 to reject the null hypothesis. Multivariable Cox regression was used to assess the relationship between prespecified variables and overall survival. Hazard ratios (HRs) and their 95% confidence intervals (95% CIs) also were calculated. Nonsignificant variables (eg, P>.05) were not removed from the final models. The assumption of proportional hazards for the multivariable Cox regression models was assessed using a test based on weighted Schoenfeld residuals versus log(time). All analyses were performed using R statistical software (version 3.1.0 or higher; The R Foundation for Statistical Computing, Vienna, Austria [http://www.r-project.org/]).
RESULTS
A total of 499 patients were enrolled in the COMPLETE study between February 2010 and February 2014 from 55 academic and community sites located throughout the United States. Locked baseline records were available for 440 patients (88.2%). Patients with a diagnosis of ALCL, AITL, or PTCL-NOS comprised approximately twothirds of the overall cohort of patients with locked baseline records (287 patients; 65.2%). After excluding patients with ALCL, those with ALK-positive disease with an IPI score of 0 to 1, and patients who discontinued the study for reasons other than death, locked baseline records and treatment records were available for 275 patients and 256 patients, respectively. The principal reason patients were removed from the baseline and treatment analyses was due to other PTCL histology (150 patients). A total of 198 patients had year 1 follow-up records, and 119 patients had year 2 follow-up records (Fig. 1) . 19 
Patient Characteristics
Baseline characteristics of the patients with nodal PTCL are presented in Table 1 . Consistent with data from the Induction regimen for 234 patients with peripheral T-cell lymphoma, not otherwise specified; angioimmunoblastic T-cell lymphoma; and anaplastic large cell lymphoma. Information regarding the treatment regimen was missing for 4 patients.
Surveillance, Epidemiology, and End Results (SEER) program, 20 a sizable percentage of patients were aged 65 years (45.1% and 44.7%, respectively, for patients in COMPLETE and SEER); the majority were male (66.3% and 58.9%, respectively), white (77.3% and 76.2%, respectively), and had advanced stage disease (Ann Arbor stage III/IV; 76.5% and 61.4%, respectively). The diagnosis of PTCL-NOS was approximately twice as frequent as ALCL or AITL (51.3% and 49.9%, respectively, for patients in COMPLETE and SEER). Characteristics of COMPLETE patients also were comparable to those of patients enrolled in the International T-Cell Lymphoma Project, 4 including median age (63.1 years vs 62 years), stage III/IV disease (76.5% vs 74.0%), and male sex (66.3% vs 61.9%).
Treatment Patterns
The intent of therapy, as defined by the treating investigator, was cure in 86.9% of the patients, whereas palliation was the intent in the remaining 13.1% of patients. A slightly higher percentage of patients who received doxorubicin were treated with curative intent (94.4%) compared with those who did not receive doxorubicin (83.3%), but a substantial majority of patients in both subgroups were treated with curative intent. The top reasons for the selection of a specific first-line regimen by the treating physicians were PTCL subtype (62.5%), clinical data from the literature (55.3%), and patient age (37.9%). Cost or insurance coverage was a factor in treatment decisions for only 2 patients (<1.0%).
Initial treatment strategies included doxorubicin in 41.8% of patients and doxorubicin plus etoposide in 20.9% of patients (Fig. 2) . The remaining patients received a variety of etoposide-based combination or singleagent regimens (15.8%), other single-agent or combination regimens (19.2%), or gemcitabine-based regimens (2.1%). Eight patients received rituximab as part of their PTCL treatment, one-half of whom were diagnosed with AITL. HSCT was performed in 52 patients (47 autologous and 5 allogeneic HSCT) as part of initial therapy, representing 20.6% of the overall study cohort. The percentage of patients receiving doxorubicin was comparable between those who underwent a transplant versus those who did not (64.0% vs 62.7%; P 5 .87). Radiotherapy was administered to 16 patients. Eleven patients initially were followed with observation/supportive care. First-line therapy was completed as planned in 64.3% of patients.
Outcomes
Response assessment was undertaken by the treating investigator according to the Revised Response Criteria for Malignant Lymphoma. 21 A complete response (CR) was reported in 57.1% of patients, a partial response in 13.3% of patients, and stable or progressive disease in 19.1% of patients. An additional 10.4% of patients were not evaluable for response. Best response was observed at a median of 132 days after PTCL diagnosis, which approximated when 6 cycles of chemotherapy administered every 3 weeks would be completed. When responses were stratified by treatment with doxorubicin versus nondoxorubicin treatment, a higher CR rate was observed in patients receiving doxorubicin (Table 2) . A higher CR rate also was reported in patients treated with curative versus palliative intent (60.6% vs 24%).
The median follow-up in the cohort was 26.0 months (interquartile range, 14.4-37.7 months). The estimated median survival was 43.0 months (95% CI, 34.5 months to not reached) (Fig. 3A) , with 12-month and 24-month survival rates of 71.7% and 58.7%, respectively. PTCL subtype and IPI score were found to have a significant impact on overall survival. Patients with ALCL had statistically significantly better overall survival compared with those with AITL and PTCL-NOS (log-rank P 5 .01) (Fig. 3B) , and patients with lower IPI scores had statistically significantly longer survival compared with those with higher IPI scores (log-rank P 5 .0002) (IPI score of 0/1 vs 2/3 vs 4/5) (Fig. 3C) . Survival by doxorubicin use is shown in Figure 4 . Survival was found to be statistically significantly longer for patients who received doxorubicin (log-rank P 5 .03). Cox proportional hazards analysis was performed to evaluate doxorubicin use, etoposide use, and overall survival while controlling for IPI score and PTCL histology (Table 3) ; the results demonstrated a trend toward statistical significance in mortality reduction among those patients treated with 22 the intent of therapy in a substantial majority of patients was cure. Treatment regimens were selected primarily based on clinical considerations, with cost or insurance coverage concerns appearing to exert little influence. Treatment-related toxicities occurred at a rate expected for patients with aggressive NHL receiving multiagent chemotherapy.
Over the past decade, the role of doxorubicin in the initial treatment of patients with nodal PTCLs other than ALCL has come into question, as evidenced by the fact that greater than one-third of patients in COMPLETE did not receive anthracyclines as frontline treatment. 4, 23, 24 However, we observed that patients who received nonanthracycline regimens had inferior response rates and worse overall survival compared with patients treated with anthracyclines. Confirmation of the reduced mortality associated with anthracycline use on multivariate analysis (controlling for IPI score and disease histology) argues against confounding by indication as the primary source of this observation. It is interesting to note that 2 recent clinical trials using combination chemotherapy regimens without doxorubicin also did not demonstrate improved response rates. 23, 24 The findings of the current study support the use of anthracyclines as an important part of the induction regimen for patients with nodal PTCL who are being treated with curative intent. 25 Among those individuals expected to tolerate anthracycline treatment, the removal of anthracyclines should be attempted only under the auspices of a clinical trial.
The inclusion of etoposide as a component of initial therapy was not found to be significantly associated with survival in the current study after controlling for disease histology and IPI score (HR, 1.00). Although the German High-Grade Non-Hodgkin Lymphoma Study Group has presented evidence supporting the addition of etoposide to the CHOP regimen (CHOEP) in patients with PTCL, this was a post hoc analysis of clinical trial data and the benefit was confined to an improvement in event-free survival among patients aged <60 years with normal lactate dehydrogenase levels. 26 Furthermore, the majority of the benefit was observed in patients with ALCL (we did not compare CHOP with CHOEP due to the small numbers of patients). Although it is conceivable that residual confounding or small patient numbers limited our ability to detect a survival difference, consideration of the current study data in conjunction with the German data (which also did not demonstrate an improvement in overall survival) suggests that any overall survival benefit associated with etoposide use in patients with PTCL is at best modest.
Despite the fact that a majority of the patients in the current study were enrolled at academic institutions, only 20.6% of the patients with nodal PTCL underwent HSCT. A recent retrospective analysis of patients with PTCL in the United States demonstrated a transplant frequency rate of only 10%. 27 The findings of the current study highlight that, regardless of the survival benefit that may be conferred by HSCT, in practice this treatment modality is used in only a small minority of patients with PTCL. As a result, efforts to improve overall survival for the majority of patients with PTCL must focus on improvements in outcomes with induction and salvage therapies.
The use of rituximab in patients with nodal PTCL deserves special attention. Approximately one-half of the patients in the current study cohort who received rituximab had AITL, a disease in which abnormal T cells are histologically associated with reactive B cells that express CD20. 28 Although it initially was believed that rituximab-induced B-cell reduction in patients with AITL would improve outcomes, a trial by Groupe d'Etude des Lymphomes de l'Adulte (GELA) demonstrated no difference in outcomes compared with the use of CHOP alone. 29 Frontline studies in patients with PTCL remain challenging to perform, largely due to the rarity of PTCL. Nearly all of the recently completed, large therapeutic Abbreviations: 95% CI, 95% confidence interval; AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; HR, hazard ratio; IPI, International Prognostic Index; Reference levels: IPI of 0 to 1, peripheral T-cell lymphoma, not otherwise specified.
Number of events was 100. a Determined using the Wald chi-square test. b Alone or in combination with another agent including etoposide. c Alone or in combination with another agent including an anthracycline. studies in PTCL were among patients with recurrent and refractory disease who were fit to enter clinical trials, and were designed to support drug approvals. As a result, there may be differences between patients studied in clinical trials and the overall population of patients with PTCL. 30 Moving forward, consideration should be given to pragmatic clinical trials to compare the effectiveness of frontline treatments in patients with PTCL with both favorable and unfavorable clinical manifestations. Such an approach would enhance enrollment through broader enrollment criteria. 31 In addition, more widespread adoption of the National Cancer Institute Central Institutional Review Board process may streamline the opening of multicenter PTCL trials at a sufficient number of sites to allow for the completion of trials of comparative effectiveness. 32 The limitations of the current study should be highlighted. Although we cannot rule out selection bias, the similarity in characteristics of the patients enrolled in COMPLETE compared with what has been reported in SEER 20 and the International T-Cell Lymphoma Project 4 suggest that the patient cohort in the current study is representative of the overall population of patients with PTCL. Furthermore, the prospective design of the current study should reduce the risk of bias and confounding compared with retrospective studies of patients with PTCL. Data quality also is a concern in observational studies. Although we did not perform on-site monitoring, the steering committee reviewed the collected data on an ongoing basis to uncover clinical inconsistencies, prompting clarification. In addition, the level of missing data was low, with few patients discontinuing the study for reasons other than death (27 patients; 5.4%). The high percentage of patients enrolled in academic sites (86.0%) is likely a reflection of the referral patterns for rare diseases. Finally, similar to any analysis of data that is not randomized, we cannot rule out residual confounding from unmeasured variables as a contributor to the current study findings.
According to the National Comprehensive Cancer Network guidelines, there is no standard of care for patients with nodal PTCL, and many regimens have been used for induction therapy. The data from COMPLETE support the concept that anthracycline-containing regimens should be used over nonanthracycline regimens for patients with common nodal subtypes of PTCL. The lack of a significant improvement in overall survival in COM-PLETE compared with historical data underscores the need for further studies of novel agents and approaches for PTCL.
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